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THE EFFECT OF MELATONIN ON THE OVARIES 
Jaclyn Starr 
ABSTRACT 
Melatonin is a very small molecule whose effects can be both detrimental and beneficial to the 
ovaries depending on its concentration.  Too much of anything is usually not good and so is the case 
with melatonin.  Very high doses can be damaging, but in the right amount melatonin may be able to 
combat various diseases and increase the chances for fertility in women. 
THE PRODUCTION OF MELATONIN 
Melatonin is an indoleamine which is produced in the pineal gland. It was first isolated 
from bovine pineal gland in 1958 and is currently classified as a hormone. This seemingly 
ambiguous hormone is found in many places in the human body and has many functions.  As 
more research is done on melatonin, more of its importance is being uncovered.  
Melatonin is synthesized and released in accordance with how much light reaches the 
eye.  When light enters the eye, the ganglion cells, which contain the photopigment 
melanopsin, send retinal photic signals to the suprachiasmatic nucleus (SCN) through the 
monosynaptic retinohypothalamic tract. The ganglion cells which contain melanopsin are 
sensitive to light with relatively short wavelengths (484 nm) (Macchi and Bruce 2004). 
There are constant rates of 
production of melatonin at night, 
but during daylight hours 
synthesis is suppressed by light 
(Macchi and Bruce 2004).  The 
mechanism which causes the light 
induced suppression and dark 
induced release of melatonin is 
due to norepinephrine. 
Norepinephrine is the input to the 
pineal gland, and melatonin is the 
output.  During the day, the 
retinal photoreceptors are 
hyperpolarized, inhibiting the 
release of norepinephrine and 
thus inhibiting the release of 
melatonin.  Conversely, the lack 
of light at night causes the 
photoreceptors to release 
norepinephrine, thereby 
activating the enzyme N-
acetyltransferase which regulates 
melatonin synthesis (Brzezinski 
1997). In addition, melatonin 
concentrations are affected by 
exercise and changing posture.  
During night hours, 
concentrations of melatonin in the 
Figure 1: Tryptophan to Melatonin. Source: Macchi and Bruce 2004 
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plasma and saliva decrease when moving from supine to standing position and vice versa 
(Macchi and Bruce 2004). 
Production of melatonin begins when pinealocytes take up the amino acid tryptophan 
from the blood.  Tryptophan is then hydoxylated and decarboxylated, thus converting it into 
serotonin.  The enzyme N-acetyl transferase (NAT) then converts the serotonin into N-acetyl 
serotonin. Hydroxyindole-O-methyl transferase (HIOMT) methylates the N-acetyl serotonin, 
converting it into indoleamine N-acetyl-5-methoxytryptamine, which is melatonin (Figure 1).  
(Macchi and Bruce 2004). Additionally, studies suggest that melatonin may be synthesized 
from serotonin in the ovaries. (Itoh et al 1999).  
After production, melatonin is released into the capillaries where 70% of it is bound to 
albumin.   Melatonin is metabolized primarily in the liver where it undergoes hydroxylation 
and conjugation into sulfate and glucuronide  (Macchi and Bruce 2004). 
A highly diffusible hormone, melatonin is found in the blood, saliva, urine, cerebro-
spinal fluid (CSF), anterior chamber of eye, retina, gut, and bone marrow, as well as in many 
reproductive fluids such as breast milk, preovulatory follicles, semen, and amniotic fluid.  
Three melatonin receptors, MT1, MT2, and MT3, have been identified  (Macchi and Bruce 
2004; Adriaens et al. 2006).  These receptors are localized in lymphocytes, prostate epithelial 
cells, granulosa cells, preovulatory follicles, spermatozoa, blood, platelets, and the mucosa and 
submucosa layers of the colon.  
Melatonin and its receptors are found in many parts of the human body, indicating 
that the hormone may have many functions rather than only one main one.  The fact that 
melatonin and melatonin receptors are found in many reproductive fluids and in preovulatory 
follicles suggests that melatonin plays a role in reproduction.   
THE FUNCTION OF MELATONIN 
Melatonin has various functions which are mediated either through specific membrane 
receptors or nuclear binding sites (Tamura et al. 2009). However, unlike other hormones, 
melatonin is unique in its ability to act as a free radical scavenger.  It is an even better 
antioxidant than glutathione, vitamin E, and mannitol, which are known as effective free 
radical scavengers. It is one of the more effective antioxidants because it permeates and 
disperses through cells easily.  Therefore it can prevent oxidative damage at any site of a cell 
(Pandey et al. 2003).  Since melatonin acts forcefully upon free radicals, it is a very important 
hormone (Macchi and Bruce 2004).    
Besides melatonin’s role as an antioxidant, it plays a part in the immune system as well. 
Maestroni (1993) showed that suppression of melatonin (which is found in lymphocytes) 
caused a decrease in thymus and spleen activity.  It also caused a decrease in the primary 
response of antibodies to T-dependent antigens.  These results were reversed with 
administration of melatonin.  In addition, constant administration of melatonin caused an 
increase in helper T cell activity and in IL-2 production (Macchi and Bruce 2004).  High 
estrogen levels cause suppression of cell mediated immune response. Melatonin acts as an 
anti-estrogen, improving immune response (Sanchez-Barcelo et al. 2005). 
Another important function of melatonin is its role in cardiac activity.  When humans 
sleep at night, heart rate and blood pressure are lowered.  It is also during the night that 
melatonin is produced.  This concurrence seems to demonstrate a link between melatonin and 
a decrease in heart rate and blood pressure.  Studies have shown that pineal extracts lower 
blood pressure in humans and in rats.  But when exogenous melatonin was administered, 
heart rate and blood pressure only went down when given during the day.  When melatonin 
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was administered at the time of endogenous melatonin production, only systolic blood 
pressure was lowered. Since melatonin has a beneficial effect on our cardiac system, it is more 
common for a stroke to occur in the morning when melatonin levels are low.  Coronary 
disease patients have low melatonin levels, making melatonin’s role in cardiac function even 
more plausible (Macchi and Bruce 2004). 
Melatonin is released in a circadian rhythm.  Therefore, it has been used to help 
regulate sleep in people with insomnia by entraining their circadian rhythm (Dubocovich 
1988).   In addition to helping regulate sleep, melatonin also regulates seasonal reproduction 
in photoperiodic animals (Macchi and Bruce 2004). These types of animals only reproduce 
during specific seasons of the year. Melatonin regulates reproduction in photoperiodic animals 
because it has a progonadotropic effect on these animals during certain seasons by increasing 
follicular stimulating hormone (FSH) concentrations and luteinizing hormone (LH) pulses 
(Dair et al. 2008). 
MELATONIN AS AN ANTIOXIDANT 
The cells in our body undergo a process called apoptosis, which is programmed cell 
death.  This occurs in order to renew the cells in our body, eliminate defective cells, and 
maintain homeostasis.  Apoptosis can be induced by growth factor deprivation, radiation 
induced DNA damage, activation of death receptors, and oxidative stress.  Overall, it is a 
beneficial process, but only if it occurs when necessary.  Excessive apoptosis can lead to an 
array of diseases such as Alzheimer’s, Parkinson’s, ischemia, stroke, and AIDS (Pandey et al. 
2003). One of melatonin’s most important features is its ability to act as a free radical 
scavenger, thus protecting against oxidative stress.  Much research has been done on the use 
of melatonin as an antioxidant since it is a safe molecule and is therefore an excellent 
candidate for use in treatments for diseases which are caused by excessive apoptosis, which is 
due to oxidative stress (Pandey et al. 2003). 
Research was done on rat hepatoma cells in order to see if serum deprivation induced 
oxidative stress, leading to apoptosis.  Serum deprivation did induce oxidative stress, but 
treatment with antioxidants such as vitamin E and melatonin prevented apoptosis.  One 
hundred (100) µM of melatonin were added to the medium six hours before serum 
deprivation.  Oxidative stress caused by serum deprivation induced production of radioactive 
oxygen species (ROS), but with melatonin pre-treatment, the level of ROS was lowered 
(Figure 2) as seen by the significant reduction in nuclear condensation and cellular blebbing 
(features of cellular apoptosis).   To ascertain that the pre-treated hepatoma cells not only 
survived but remained functional, they were re-plated in complete media.  Most of the cells 
divided; they doubled three times in seventy two hours. In contrast, serum-deprived cells 
(without melatonin treatment) died within ninety six hours (Pandey et al. 2003). 
Another antioxidant, glutathione, is a tripeptide which acts as a free radical scavenger 
by reducing oxidative stress.  In the latter experiment, glutathione levels were tested in the 
serum deprived cells and in the melatonin treated serum deprived cells.  In the untreated cells, 
glutathione levels were decreased, but in the melatonin pre-treated cells, glutathione levels 
remained the same  (Pandey et al. 2003).  This study demonstrates that melatonin not only has 
an anti-apoptotic effect as an antioxidant, but also has a protective effect over other 
antioxidants. 
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MELATONIN AND WOMEN 
Melatonin affects the 
female reproductive system 
by acting upon the ovaries 
both directly and indirectly. It 
acts indirectly on the ovaries 
by acting on gonadotropin 
releasing hormone (GnRH), 
thereby effecting the release 
of gonadotropins (GnRH is 
responsible for the release of 
LH and FSH from the 
anterior pituitary gland) 
(Romeu et al. 2010).  
Melatonin acts on the ovaries 
directly through its 
antioxidant and anti-apoptotic 
properties, as well as its 
regulation of LH mRNA in 
the ovaries (Tamura et al. 
2009).  
One indication that 
melatonin is involved in 
reproduction is that melatonin 
levels decrease at the start of 
puberty.  This may hint to melatonin’s role in reproduction because high levels of melatonin 
are known to inhibit ovulation (Macchi and Bruce 2004).  Secondly, the concentration of 
melatonin in human preovulatory follicular fluid is three times more than in the plasma and 
melatonin and its precursors are found in human ovary extracts.  For example, NAT and 
HIOMT are found in human ovarian homogenates (Itoh et al. 1999). In addition to melatonin 
itself, MT1 and MT2 receptors are also found in ovarian extracts such as ovarian granulosa, 
luteal cells of humans, and rat ovaries. The binding site for the receptors has been detected in 
the granulosa cell membrane.   
There are two possibilities for the source of the melatonin found in the female 
reproductive system.  It is possible that it is synthesized in the ovary and then released 
directly into the follicular fluid, or it may be derived from the circulation.  The latter seems 
more likely because when infertile women were given a 3 mg tablet of melatonin (taken 
orally), there were higher levels of melatonin in the follicular fluid (Tamura et al. 2009).   
High or low melatonin levels in rats can affect their ovaries. In an experiment done to 
determine the effects of melatonin on rat endometrial morphology and embryo implantation, 
results indicated that melatonin had a positive effect on the endometrium by allowing for 
better implantation of embryos (probably by raising progesterone levels) (Soares et al. 2003).  
Rats are non-photoperiodic, just like humans.  Melatonin was administered to the rats 
in large doses in the afternoon of their proestrus phase (the phase proceeding ovulation).  As a 
result, the surge in LH which normally causes ovulation was prevented, not allowing for 
ovulation. In another experiment, when rats were given exogenous melatonin, ovarian weight 
Figure 2: The effect of ROS on cells treated with melatonin versus 
control cells.  Source: Pandey et al. 2003 
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was decreased. But, when the rats were subjected to prolonged light, decreasing the high 
melatonin levels, an increase in ovarian weight was observed  (Soares et al. 2003).   
This antigonadotropic effect was seen not only when melatonin levels were too high, 
but also when melatonin levels were too low. When melatonin production was suppressed in 
rats, either by pinealectomy or light, precocious puberty, ovarian atrophy, chronic 
anovulatory state, permanent estrous condition, and hyperprolactinemia were observed. 
Pinealectomy induced a prolonged estrous stage in the rats, possibly by raising estrogen levels 
and lowering progesterone levels  (Dair et al. 2008).  Moreover, when rats underwent a 
pinealectomy, there was an increase in atretic follicles in the ovaries (Tamura et al. 2009). 
Atresia is hormone controlled apoptosis; approximately ninety nine percent of ovarian follicles 
undergo this degenerative process; the rest proceed to the preovulatory stage (Manabe et al. 
2008). Pinealectomy  of rats in another experiment resulted in overgrowth of the ovarian 
stroma (Romeu et al. 2010). 
From these experiments on rats, it seems that high levels of melatonin have 
antigonadotropic effects (indirectly affecting the ovaries) resulting in a lack of ovulation, and 
low levels of melatonin cause an increase in atretic follicles and decrease in ovarian weight. 
But it should be noted that high levels appear to improve the endometrium for implantation 
by having an effect on hormones such as estrogen and progesterone.  It is also possible that in 
humans, high melatonin levels are detrimental to fertility because infertility may be a result of 
low estrogen levels and high melatonin levels (Macchi and Bruce 2004).   
In women with stress induced, exercise induced, or functional hypothalamic 
hypogonadism, melatonin levels are higher than normally present.  Additionally, women with 
functional amenorrhea, have high melatonin levels which are inversely related to their 
estrogen levels, suggesting a relationship between high melatonin concentrations and 
hypothathalamic-pituitary-gonadal hypofunction which can cause temporary infertility by 
preventing menstruation in women. In one study, exogenous melatonin and progestagen were 
given to women; as a result LH secretion decreased, not allowing for ovulation.  Although the 
luteal phase increase in progesterone was blocked, FSH and estradiol were not affected  
(Macchi and Bruce 2004). 
The relationship between melatonin and estrogen was also studied in breast cancer 
patients.  High melatonin levels decreased the amount of estrogen, and low melatonin caused 
an increase in estrogen.  In breast cancer patients, tumors are sometimes estrogen-dependent.  
These women were treated with estrogen inhibitors such as tamoxifen, which is a drug that 
acts as an estrogen receptor antagonist and agonist. Melatonin acts as an anti-estrogen as well, 
but in a different manner; it interacts with the estrogen receptor signaling pathway. Melatonin 
binds to its own receptors and causes a decrease in expression of estrogen receptors, thereby 
blocking estradiol from binding to the estrogen receptors (Sanchez-Barcelo et al. 2005).  
Therefore, infertile women may have high levels of estrogen which could possibly be treated 
with administration of melatonin. 
Low levels of melatonin in human ovaries may also be unfavorable by affecting the 
ovaries directly. Many studies provide evidence that follicular cell death during atresia occurs 
through apoptosis. Many women who are having ovarian failure such as premature ovarian 
failure, polycystic ovary syndrome, oophoritis, or unexplained infertility, may have these 
disorders due to a large number of follicular cell deaths via apoptosis.  In order for apoptosis 
to occur, the cell’s mitochondrial membrane must become more permeable, so as to release 
pro-apoptotic factors. Melatonin has been shown to directly inhibit the permeability of 
transition pores (a protein pore), causing anti-apoptotic effects.   
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An experiment was done in which mice were injected with either xenogenic anti-
ovarian antibodies or allogenic anti-ovarian antibodies.  One hour before antibody injection, 
melatonin was administered (5 mg/kg).  In the control mice, exogenous melatonin had no 
effect on the ovaries, but in the mice which had been injected with xenogenic anti-ovarian 
antibodies, melatonin reduced the negative effects caused by the antibodies; it improved 
oocyte quality and caused a decrease in the number of follicular cell deaths by apoptosis. 
Melatonin reversed the antagonistic effects of anti-ovarian antibodies on the mouse ovaries, 
but it did not protect against the larger immune reaction of the xenogenic antibodies on a 
systemic level. On the other hand, melatonin administration in mice injected with allogenic 
anti-ovarian antibodies had no effect (Voznesenskaya et al. 2007).   
 In addition to providing anti-apoptotic factors, melatonin in the follicles can scavenge 
free radicals such as radioactive nitrogen species (RNS) and ROS, as mentioned above.  The 
capability of melatonin to act as a free radical scavenger is especially important because 
ovulation stimulates a local inflamatory response, causing inflammatory cells such as 
macrophages and neutrophils to produce free radicals such as ROS and RNS, which induce 
apoptosis in ovarian cells.  Higher melatonin levels in ovarian follicles offers the ovarian cells a 
greater chance of maturing and developing (Tamura et al. 2009). Therefore, if a woman’s 
melatonin levels are too low, there may be an increase in the percentage of follicular deaths 
which would result in a lower number of follicles that have the potential for ovulation.  
Clearly, melatonin levels must be maintained within a certain range, since very high and very 
low levels can prevent ovulation, leading to infertility. 
Very few follicles mature and become capable of releasing their ovum for fertilization 
purposes. The maturing follicle is filled with follicular fluid which contains water, electrolytes, 
serum proteins, and steroid hormones secreted by granulosa cells.  Melatonin affects sex 
steroid production at different phases of follicular growth by regulating the steroidogenic 
enzyme, which activates gene expression in thecal and granulosa cells.  Melatonin has been 
proven to alter granulosa cell steroidogenesis and follicular function.  As follicles mature, they 
shift from dependency on FSH to LH.  The process by which follicles are selected to continue 
maturing may be linked to the timing of mRNA expression encoding LH receptors in 
granulosa cells.   Melatonin may directly affect the ovaries by regulating LH mRNA 
expression; melatonin treatment (10 pM-100 nM) increased the LH receptor mRNA 
expression in granulosa cells  (Tamura et al. 2009).  This confirms that higher levels of 
melatonin in the ovaries can be beneficial, but what concentrations are too high?  
Research was done in order to find a melatonin concentration that would protect 
female oocytes without being toxic.  This experiment was specifically performed to find a way 
for young women who are undergoing treatments such as chemotherapy and radiation to 
Figure 3: The granulosa cells of the ovaries, which each house an oocyte, go through three major phases: the follicular, 
diffuse, and antral stages. Source: Adriaens et al. 2006 
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retain fertility.  Mouse follicles were cultured in vitro and different concentrations of 
melatonin were added to each. Ovulation was then stimulated.  Two (2) mM of melatonin was 
found to be toxic (this is about four thousand times more than physiological melatonin 
concentrations in the follicular fluid); it affected follicular differentiation leading to a 
decreased amount of antral follicles  (Adriaens et al. 2006). 
One (1) mM negatively influenced oocyte development, and 100 µM influenced 
steroidogenesis. Ten (10) µM was the highest concentrations that had no negative effect on 
the follicular system. This dosage could possibly be used to protect female ovaries.  
Additionally, progesterone levels increased significantly in follicles with 100 µM and 1 mM of 
melatonin.  After ovulation was stimulated, progesterone levels increased in all cases except 
for with 2 mM melatonin.  In the control groups, estradiol increased exponentially, but in 
follicles with 1 or 2 mM of melatonin, estradiol amounts were much lower.  As seen by the 
results in Figure 4, large doses of melatonin caused a reduction in the number of granulosa 
Figure 4 :Morphological changes of follicles over a 12 day period under different melatonin 
concentrations Source: Adriaens et al. 2006 
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cells.  But by day twelve, most of the follicles reached the antral stage, with concentrations of 
up to 1 mM melatonin (Adriaens et al. 2006).   
This experiment only used three mice (six ovaries) for evaluation; this is a very small 
control group making its validity questionable.  Everyone has varying levels of hormones, 
such as estrogen, progesterone and melatonin, in circulation so a larger number of ovaries 
should have been used in this study. On the other hand, this study was done well because they 
used concentrations of melatonin spanning physiological and pharmacological follicular fluid 
concentrations (1nM-2mM).  According to this study, there would be no health hazard (in 
regards to fertility) for women to take 3 mg tablets of melatonin (the normal dosage found 
over-the-counter).   
 In another experiment, three week-old mice were whole-body irradiated with gamma-
radiation.  Gamma radiation causes an increase in atresia of ovarian follicles.  The purpose of 
this experiment was to observe if melatonin provided a protective effect against radiation. One 
group of mice was treated with 10 µg of melatonin before radiation, and another was treated 
with 100 µg.  After radiation, the ovaries were taken out and examined.  The number of 
follicles (including normal and atretic) was about one hundred and twenty five in the largest 
cross sections; in the irradiated mouse ovaries, the number of follicles was reduced to about 
one hundred and three. Primordial follicles were the most sensitive to radiation; melatonin 
treatment seemed to protect these follicles from radiation. Ten (10) µg of melatonin did not 
have a large protective effect on the primary follicles from radiation, but 100 µg did display a 
protective effect on them. But lower melatonin concentration did have a protective effect on 
preantral and antral follicles.  Different concentrations of melatonin have protective effects 
against radiation at different stages of follicular development  (Kim and Lee 2000).   
As opposed to most of the previous studies mentioned, one study found that melatonin 
increased follicular atresia.  Research was done to study the effects of pineal indoles 
(including melatonin) on gonadotropin-induced ovulation in mice.  To stimulate ovulation, 
mice were injected with PMSG (pregnant mare serum gonadotropin) and hCG (human 
chorionic gonadotropin). Then various pineal indoles, at a dose of 0.2 mg/25 g body weight, 
were administered.  After the mice were sacrificed, the ovaries were removed and examined.   
Although ovarian weight and quality remained the same, the number of atretic follicles 
appeared to increase in the mouse ovaries which had been injected with melatonin.  Plasma 
levels of estradiol and progesterone were decreased (Chan and Ng 1995).   
The two latter experiments discussed (on gamma radiation and on pineal indoles) both 
used young mice which were prepubertal.  Puberty in humans causes a decrease in 
endogenous melatonin production, as well as other hormonal changes.  When examining 
whether melatonin has protective effects on follicles for the purpose of helping prepubertal 
females, using prepubertal mice is appropriate.  Otherwise, mature mice should be used for 
experimentation because hormone levels and interactions would be more similar to that in 
mature women.   
FUTURE RESEARCH ON MELATONIN 
As seen by the experiments and research done on melatonin, it is apparent that the 
indoleamine affects the reproductive system.  It appears that melatonin is beneficial in high 
concentrations when it is present in the ovaries because it directly decreases apoptosis and 
acts as a free radical scavenger.  Therefore, low melatonin levels in the ovaries are detrimental 
to fertility.  On the other hand, high melatonin concentrations in the blood can inhibit 
ovulation by inhibiting the surge in LH.  It is necessary to determine the concentrations of 
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melatonin that will be most beneficial in increasing ovulation by protecting and helping oocyte 
maturation, without being too high to be antigonadotropic.  In addition, research should be 
done to see if melatonin can be directly administered into the ovaries (in order to decrease 
apoptosis) without too much of it entering circulation and possibly inhibiting ovulation (by 
inhibiting the release of GnRH).  
Moreover, more research needs to be done on finding a concentration of melatonin 
that has protective properties on oocytes (by acting as free radical scavengers) without having 
detrimental effects.  This would be beneficial to young women undergoing chemotherapy or 
radiation treatments whose fertility in the future might be at risk. Ten micromoles of 
melatonin is a dose that should be experimented with further. 
Additional work should be done on the relationship between melatonin and estrogen.  
A few of the experiments done showed that low levels of melatonin, as a result of 
pinealectomy, raised estrogen levels and caused an increase in atretic follicles.  On the other 
hand, other research indicated that high levels of melatonin and low estrogen levels were 
detrimental to fertility.  
Melatonin could also be used as a supplement for treatments of various disorders since 
it is generally safe (Brzezinski 1997).  As an antioxidant and mitochondrial membrane 
permeability transition pore inhibitor, melatonin may be a good candidate to help in the 
management of cancer, Alzheimer’s disease, diabetes, and viral infections (Tamura et al. 
2009).   Research has shown that melatonin can fight against tumors by reducing vascular 
endothelial growth factor (Romeu, et al. 2010).  It is also permeable enough to disperse 
throughout cells and can even penetrate the nucleus where it can protect DNA from oxidative 
damage, reducing the risk of cancer  (Meki et al. 2001). 
CONCLUSION 
 Melatonin has a relationship with estrogen and other hormones, has an anti-
apoptotic effect, and regulates LH mRNA.   With these properties melatonin can be beneficial 
as it may help increase fertility in women who are infertile, prevent damage in diseases where 
there is too much apoptosis, and possibly protect the ovaries from radiation.  Although more 
research has to be done on melatonin and the doses which work best in each case, it seems 
that the hormone will play a role in various therapies  in the future.  
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